GlassScriptPhysician profile
Daphne Dadzie
NPI 1083945687
$785.25
in general payments reported to CMS, 2019-2025
13 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.14 · 2020: $62.08 · 2021: $14.54 · 2022: $111 · 2023: $85.24 · 2024: $180 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $252.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $97.78 | 2020-2024 | Zepbound, Jardiance |
| Amryt Pharma Holdings LTD | $79.29 | 2022-2023 | Myalept |
| Sanofi-Aventis U.S. LLC | $70.16 | 2019-2024 | |
| Abbvie INC. | $70.16 | 2024-2025 | |
| Abbott Laboratories | $66.65 | 2022-2025 | Freestyle Libre 3 |
| Insulet Corporation | $49.91 | 2024-2025 | Omnipod |
| Exact Sciences Corporation | $23.02 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $18.20 | 2025 | Tepezza |
| Antares Pharma, INC. | $17.44 | 2024 | Xyosted |
| Novartis Pharmaceuticals Corporation | $14.74 | 2024 | |
| Halozyme INC | $13.71 | 2023 | |
| Janssen Pharmaceuticals, INC | $11.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daphne Dadzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.